ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). - Wikidata - awgldk - TriplyDB

ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).

ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).

http://www.wikidata.org/entity/Q38061883

about

Current concepts in diagnosis and treatment of chronic lymphocytic leukemia Next-generation surveillance strategies for patients with lymphoma The Comparative Diagnostic Features of Canine and Human Lymphoma.Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study.Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation.Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China.Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey.Management of chronic lymphocytic leukemia.Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients--preliminary report.Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice.Genetic lesions in diffuse large B-cell lymphomas Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.Radiotherapy as an effective treatment modality for follicular lymphoma: a single institution experience.Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia Ibrutinib: a paradigm shift in management of CLL.Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era.FDG-PET imaging in hematological malignancies A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.Extranodal involvement in young patients with diffuse large B-cell lymphoma: distribution, prognostic value and treatment options.Treatment of elderly patients with chronic lymphocytic leukemia: an unmet cinical need.Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: a review of pharmacokinetics and clinical trial outcomes.Treatment approaches to asymptomatic follicular lymphoma.Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients.Accelerated therapeutic progress in diffuse large B cell lymphoma.How we manage follicular lymphoma.Profile of pacritinib and its potential in the treatment of hematologic disorders.Chemotherapy-free treatment in patients with follicular lymphoma.Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia?Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.XI. Management of paediatric and adult non-Hodgkin lymphoma: what lessons can each teach the other?Rethinking clinical response and outcome assessment in a biologic age.Flow cytometry immunophenotyping in integrated diagnostics of patients with newly diagnosed cytopenia: one tube 10-color 14-antibody screening panel and 3-tube extensive panel for detection of MDS-related features.Management of Hematologic Malignancies: Special Considerations in Pregnant Women.Genetic landscape and deregulated pathways in B-cell lymphoid malignancies.

P2860

Q26770471-ACA14043-C5F9-4A64-9E1E-F2EC22A04836 Q28084956-198DD014-CEAC-48A1-A8DD-1D4B368765B6 Q30401307-123ACC7B-FC9E-4AEE-BAD9-D3C566003AC6 Q33412158-5B36F91B-A2CE-486B-A119-E73A2AA1F4F3 Q33417548-37454AB8-5F2F-4976-9011-782ADD674202 Q33622342-4C8AC4E6-9BE8-4B40-A344-9AB9865EF1FB Q33649977-BDB977E3-8684-492C-93FB-603A493A9125 Q33673144-F46D5176-3163-488A-92A1-2428401B6501 Q33695912-29C331CF-6F44-4465-BF10-C4DBFC327FBE Q34663865-FEF5F08A-90D8-47BA-B41B-07CDA31B0815 Q34704085-6F54FD18-DDD7-4028-B66B-62B8D8849E7F Q34769213-988AF540-D678-443D-8835-8613F37DDD9E Q35236063-47E50BCC-5CE2-4C60-85AC-7AC04B8F5914 Q35741605-8A0155AE-BF6F-42E9-8347-9FFAABEAF67D Q35800846-2F79D09C-7802-49D6-B330-E6A368822144 Q35917095-9F03A1AD-921F-4343-8238-04771C11E782 Q35974341-18B601DA-5DF2-49A9-B541-E6FB33A86E63 Q36192439-15A0F9B7-A3E5-41EB-9C9D-4D69E3AC94C2 Q36448074-BD0D2FFA-4081-4A57-8375-BE714AC3200E Q36490049-AFA846BF-8060-45A0-ABA1-6379F91A81E7 Q36739295-07E1B0CA-6B1E-49EF-B0E9-CE365501EBB3 Q37389643-C3358102-CCB9-430B-9FAB-6DCB6E582000 Q37632114-40D14B73-E93A-479D-B571-0527966F871B Q37672472-F191C4C9-E221-46E5-B204-27FE69086920 Q37697317-A5EC0A70-D09F-4A0A-B4B1-5DA9AEA9DEC0 Q38132818-D47BBCE1-EBCA-4A07-8B53-6F64FCEB9590 Q38152510-0F82BC47-5D77-45B3-8AD0-800295A49D83 Q38161963-F04547BE-9C73-4C70-B380-136F2584463A Q38174058-C5D9AEBB-930E-46E8-B969-FEAF9311A17C Q38174498-BC305ADF-197F-459B-99DF-541217547E19 Q38191811-ED70C3E7-09F5-4323-BF82-5E0841730389 Q38244524-66B8C8BC-9D5B-4430-A419-052A3D938F4B Q38317235-70B9D54B-D061-442B-AD40-1540B9D08DBA Q38344296-C0323C99-A228-43C6-BD84-F0705D4E528D Q38387292-700A4FC4-506A-407F-91E1-072E34BEFA9B Q38389260-44C7738D-B688-4530-BCF4-0D4055519949 Q38480777-F392390A-216A-49BB-B100-04ED96E5D20F Q38482013-38CE4485-FBD7-4319-B681-FAFABD345F03 Q38594889-98A5CF50-5AF9-4433-80A6-02D3CAB86E01 Q38669131-6031373E-252F-481D-91E0-445744C562A4

P2860

ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).

http://www.wikidata.org/entity/Q38061883

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

ESMO Guidelines consensus conf ...... ic lymphocytic leukemia (CLL).

@en

type

label

ESMO Guidelines consensus conf ...... ic lymphocytic leukemia (CLL).

@en

prefLabel

ESMO Guidelines consensus conf ...... ic lymphocytic leukemia (CLL).

@en

P1433

Q38061883-F5029BD9-6774-4A38-B974-46FC89B9AC67

P1476

Q38061883-6C9C1CB6-9381-4154-96A5-169C8DD04651

P2093

Q38061883-82946B95-A0F1-4D54-AEFE-9055F1E6B456

Q38061883-8546968B-BFA9-405C-8E2A-76728A12F7EF

Q38061883-85690C9C-D2E4-49DE-BFAA-43BE6ED62ED4

Q38061883-92234E44-40BC-47CF-8136-297B47F51498

Q38061883-93B561C1-83A3-498F-B2B1-F4AC85F05ADF

Q38061883-9F1C4B0D-8A37-4613-8941-0982099B61A2

Q38061883-A042AAE2-2CBC-46AC-9D15-D6C4B3D2B5B4

Q38061883-A43BF8EE-89D5-45F0-A02B-152C7A77BA77

Q38061883-A7ED1D6F-81B2-4B8C-93A1-D7D0C1EE34C7

Q38061883-BB0B93C5-30B5-4225-BBDB-32C1FFF7C955

P2860

Q38061883-011F7F35-50AC-45ED-BFF2-911265BD92D9

Q38061883-02BE8E4E-CCFA-4488-912D-BA276CEFE7E7

Q38061883-071237C4-B2C6-414F-9680-E678C7A55DC0

Q38061883-07E9F408-0D35-48E2-A0CA-4A273422FD5E

Q38061883-095540C2-9DFC-4DB9-8368-223E42E12C0F

Q38061883-0EC143BE-A21A-46F7-84A1-541D45F89D10

Q38061883-0F5355A1-2205-4A16-B232-8B03CF55CC68

Q38061883-17EFB63C-3289-44B5-94DB-A0CC77D4C4E1

Q38061883-18D21477-9C0F-4148-A28C-E09F54F32B81

Q38061883-1BC0033C-860E-4072-9B2D-3E76F0868263

P304

Q38061883-F28B6929-9A8D-4DE6-9D66-9B064F04F089

P31

Q38061883-692AF776-BE31-4F86-8B49-F2AD18DCA737

P356

Q38061883-C574250C-6B23-4C86-B8EF-FB2F3FB7F6A9

P433

Q38061883-38ED9073-D2C1-41E8-8439-56652243F9DD

P478

Q38061883-B3230FFA-67D6-4441-A7FD-CCF756E88795

P50

Q38061883-8463C270-54E7-40B7-ABFA-AB092D65F04C

P577

Q38061883-9D5ED7FD-850E-4EB8-9231-229C4261292F

P5875

Q38061883-D3424B78-5FD3-424D-9184-24969A855700

P698

Q38061883-9191EC2B-1D9D-4AF4-9F7D-21455872B95C

P921

Q38061883-BE635B2C-058E-44C5-BE4C-552F2B353536

P932

Q38061883-BC45CF5F-BB89-4CDC-9856-A0086A04177D

P356

P1433

Annals of Oncology

P1476

ESMO Guidelines consensus conf ...... nic lymphocytic leukemia (CLL)

@en

P2093

C McNamara

http://www.w3.org/2001/XMLSchema#string

E Kimby

http://www.w3.org/2001/XMLSchema#string

E Montserrat

http://www.w3.org/2001/XMLSchema#string

F Caligaris-Cappio

http://www.w3.org/2001/XMLSchema#string

J Walewski

http://www.w3.org/2001/XMLSchema#string

M Dreyling

http://www.w3.org/2001/XMLSchema#string

M Federico

http://www.w3.org/2001/XMLSchema#string

M Ghielmini

http://www.w3.org/2001/XMLSchema#string

M Pfreundschuh

http://www.w3.org/2001/XMLSchema#string

P Dreger

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

TP53 mutation and survival in chronic lymphocytic leukemia.

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

Genomic aberrations and survival in chronic lymphocytic leukemia

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98

P304

561-576

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDS517

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233750990

http://www.w3.org/2001/XMLSchema#string

P698

23175624

http://www.w3.org/2001/XMLSchema#string

P921

P932

6267877

http://www.w3.org/2001/XMLSchema#string